Data from a Phase I trial of Avmapki Fakzynja also supports the regimen's tolerability and suggests its potential activity in ...

Cero will use Invivoscribe's multiparametric flow cytometry assay to detect minimal residual disease in patients and evaluate the therapy's efficacy.

The organizations launched the center with a $20 million CZI grant to build on the success of the first personalized CRISPR base-editing therapy.

The Phase II trial will compare progression-free survival in lung cancer patients treated according to their molecular subtypes.

NEW YORK – Ambry Genetics found that a web-based, patient-facing risk-stratification platform successfully identified nearly all patients who meet genetic testing criteria for hereditary cancer ...

NEW YORK – RedHill Biopharma has begun recruiting patients with metastatic castration-resistant prostate cancer to a Phase II trial testing the combination of opaganib, its small molecule sphingosine ...

NEW YORK – The US Food and Drug Administration on Wednesday granted accelerated approval to Dizal's oral EGFR inhibitor Zegfrovy (sunvozertinib) as a treatment for patients with locally advanced or ...

NEW YORK – Iksuda Therapeutics sees an opportunity to help patients who have relapsed on AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) by using a novel HER2-targeted antibody-drug ...

NEW YORK – 4D Molecular Therapeutics on Wednesday said it will reduce its workforce by 25 percent, cutting primarily early-stage R&D and support functions. The layoffs are part of the Emeryville, ...

NEW YORK – A new law in Texas could pave the way for more community cancer practices to provide CAR T-cell therapy. At least that's the goal, according to Brooks Landgraf, a Republican representative ...

NEW YORK – Neurogene this week said it has taken steps to begin a registrational trial to evaluate NGN-401, its investigational gene therapy for Rett syndrome, after reaching an agreement with the US ...

NEW YORK – Iksuda Therapeutics on Monday said it will expand an ongoing Phase I trial of the HER2-targeted antibody-drug conjugate (ADC) IKS014 in solid tumors to US sites. The Newcastle, ...